We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Roche's Infectious Disease Portfolio To Include HCV Immunodiagnostics

By HospiMedica staff writers
Posted on 26 Nov 2007
Hepatitis C virus (HCV) infections frequently result in chronic liver disease. They represent a major cause of death through the development of liver cirrhosis and liver cancer. HCV antibody tests are used for the primary diagnosis of HCV virus infection in patients with suspected liver disease. Positive anti-HCV results indicate the need for further investigation such as nucleic acid testing for viral RNA. Prognosis of HCV infection can be improved by anti-viral treatment, specifically interferon, and can be monitored using diagnostic tests.

Roche (Basel, Switzerland) announced licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. (Raritan, NJ, USA) and Novartis Vaccines & Diagnostics (Frimley/Camberley, UK) in the field of HCV diagnostics. Under the terms of the licensing agreement Ortho-Clinical Diagnostics, Inc. and Novartis Vaccines & Diagnostics granted Roche Diagnostics a worldwide royalty-bearing license under their broad patent portfolio for HCV in the field of immunodiagnostics. The agreement also includes cross licensing of patents owned by Roche Diagnostics. Financial terms of the deal were not disclosed.

The licensing agreement for HCV immunoassays will enable Roche Professional Diagnostics to expand its comprehensive product range in infectious diseases and to become a major player in this field, having already achieved a leading position in nucleic acid testing for hepatitis and retroviruses.

"We are pleased to have reached an agreement that provides Roche Diagnostics worldwide access to HCV immunoassays. This agreement will strengthen Roche's position in infectious disease diagnostics and will drive further growth of our immunoassay business worldwide,” commented Dirk Ehlers, head of Roche Professional Diagnostics.

Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology, and active in other therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders, and diseases of the central nervous system (CNS).


Related Links:
Roche
Ortho-Clinical Diagnostics
Novartis Vaccines & Diagnostics

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Ultrasonic Cleaner
Cole-Parmer Ultrasonic Cleaner with Digital Timer
New
LED Examination Lamp
Clarity 50 LED

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024